Abstract:What's new? Tamoxifen reduces mammographic density via effects on breast tissue. But while mammographic density is a proxy for therapeutic response, the extent of response can differ significantly among patients. Here, using information from a mammography screening program in Sweden, the authors investigated whether baseline characteristics of breast tissue influence changes in breast density associated with tamoxifen. Analyses show that women with increased baseline breast density experience greater density decrease with tamoxifen. Tamoxifen‐associated decreases in density were further linked to elevated expression of Ki67 and stromal progesterone receptor. The results indicate that density and histological features of breast tissue modulate tamoxifen response. Tamoxifen prevents recurrence of breast cancer and is also approved for preventive, risk‐reducing, therapy. Tamoxifen alters the breast tissue composition and decreases the mammographic density. We aimed to test if baseline breast tissue composition influences tamoxifen‐associated density change. This biopsy‐based study included 83 participants randomised to 6 months daily intake of placebo, 20, 10, 5, 2.5, or 1 mg tamoxifen. The study is nested within the double‐blinded tamoxifen dose‐determination trial Karolinska Mammography Project for Risk Prediction of Breast Cancer Intervention (KARISMA) Study. Ultrasound‐guided core‐needle breast biopsies were collected at baseline before starting treatment. Biopsies were quantified for epithelial, stromal, and adipose distributions, and epithelial and stromal expression of proliferation marker Ki67, oestrogen receptor (ER) and progesterone receptor (PR). Mammographic density was measured using STRATUS. We found that greater mammographic density at baseline was positively associated with stromal area and inversely associated with adipose area and stromal expression of ER. Premenopausal women had greater mammographic density and epithelial tissue, and expressed more epithelial Ki67, PR, and stromal PR, compared to postmenopausal women. In women treated with tamoxifen (1–20 mg), greater density decrease was associated with higher baseline density, epithelial Ki67, and stromal PR. Women who responded to tamoxifen with a density decrease had on average 17% higher baseline density and a 2.2‐fold higher PR expression compared to non‐responders. Our results indicate that features in the normal breast tissue before tamoxifen exposure influences the tamoxifen‐associated density decrease, and that the age‐associated difference in density change may be related to age‐dependant differences in expression of Ki67 and PR.

Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women

Endogenous sex hormone levels and mammographic density among postmenopausal women

Association between sex hormones, glucose homeostasis, adipokines, and inflammatory markers and mammographic density among postmenopausal women

The heritability of mammographic breast density and circulating sex-hormone levels: two independent breast cancer risk factors

Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study

Sex hormones and breast cancer risk and prognosis

A study on the association among serum insulin,IGFBP3, and endometrial cancer risk in Chinese women

Associations between mammographic density and tumor characteristics in Chinese women with breast cancer

Influence of Factors on Mammographic Density in Premenopausal Chinese Women

Biological Mechanisms and Therapeutic Opportunities in Mammographic Density and Breast Cancer Risk

Mammographic Density in Relation to Breast Cancer Risk Factors among Chinese Women

Cigarette smoking and mammographic breast density in post-menopausal women from the EPIC Florence cohort

Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmö Preventive Project

Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up

Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change

The Relationship Between Terminal Duct Lobular Unit Features and Mammographic Density among Chinese Breast Cancer Patients

Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS)

Distribution of mammographic density and its influential factors among Chinese women

Breast Cancer Risk Factors and Mammographic Density among High-Risk Women in Urban China

Associations between quantitative measures of mammographic density and terminal ductal lobular unit involution in Chinese breast cancer patients

Longitudinal history of mammographic breast density and breast cancer risk by familial risk, menopausal status, and initial mammographic density level in a high risk cohort: a nested case–control study